Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Do Hedge Funds and Insiders Love Mylan Inc. (NASDAQ:MYL)?

Is Mylan Inc. (NASDAQ:MYL) undervalued? The smart money is getting more optimistic. The number of bullish hedge fund positions went up by 9 lately.

At the moment, there are a multitude of methods investors can use to monitor publicly traded companies. A couple of the most innovative are hedge fund and insider trading interest. At Insider Monkey, our research analyses have shown that, historically, those who follow the best picks of the elite money managers can trounce the market by a very impressive amount (see just how much).

Mylan Inc. (NASDAQ:MYL)

Equally as key, optimistic insider trading activity is another way to parse down the financial markets. As the old adage goes: there are plenty of stimuli for a corporate insider to cut shares of his or her company, but just one, very simple reason why they would behave bullishly. Plenty of empirical studies have demonstrated the valuable potential of this tactic if you understand what to do (learn more here).

With all of this in mind, it’s important to take a gander at the latest action surrounding Mylan Inc. (NASDAQ:MYL).

How are hedge funds trading Mylan Inc. (NASDAQ:MYL)?

At year’s end, a total of 31 of the hedge funds we track held long positions in this stock, a change of 41% from the third quarter. With hedge funds’ positions undergoing their usual ebb and flow, there exists an “upper tier” of key hedge fund managers who were boosting their holdings meaningfully.

Of the funds we track, Paulson & Co, managed by John Paulson, holds the biggest position in Mylan Inc. (NASDAQ:MYL). Paulson & Co has a $673 million billion position in the stock, comprising 4.1% of its 13F portfolio. On Paulson & Co’s heels is Sectoral Asset Management, managed by Jérôme Pfund and Michael Sjöström, which held a $148 million position; 2.6% of its 13F portfolio is allocated to the company. Remaining hedge funds that hold long positions include D. E. Shaw’s D E Shaw, Samuel Isaly’s OrbiMed Advisors and Steven Cohen’s SAC Capital Advisors.

As industrywide interest jumped, some big names have been driving this bullishness. OrbiMed Advisors, managed by Samuel Isaly, assembled the largest position in Mylan Inc. (NASDAQ:MYL). OrbiMed Advisors had 83 million invested in the company at the end of the quarter. also initiated a $14 million position during the quarter. The following funds were also among the new MYL investors: Jim Simons’s Renaissance Technologies, Ken Heebner’s Capital Growth Management, and Brian Ashford-Russell and Tim Woolley’s Polar Capital.

How have insiders been trading Mylan Inc. (NASDAQ:MYL)?

Insider buying is particularly usable when the company in question has experienced transactions within the past 180 days. Over the last 180-day time frame, Mylan Inc. (NASDAQ:MYL) has experienced zero unique insiders purchasing, and 9 insider sales (see the details of insider trades here).

With the returns shown by Insider Monkey’s studies, everyday investors should always keep an eye on hedge fund and insider trading sentiment, and Mylan Inc. (NASDAQ:MYL) applies perfectly to this mantra.

Click here to learn more about Insider Monkey’s Hedge Fund Newsletter

Insider Monkey’s small-cap strategy returned 29.2% between September 2012 and February 2013 versus 8.7% for the S&P 500 index. Try it now by clicking the link above.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!